Please confirm you are human (Sign Up for free to never see this)
← Back to Search
The F-Box Domain-Dependent Activity Of EMI1 Regulates PARPi Sensitivity In Triple-Negative Breast Cancers.
Antonio Marzio, J. Puccini, Y. Kwon, Natalia Maverakis, A. Arbini, P. Sung, D. Bar-Sagi, M. Pagano
Published 2019 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The BRCA1-BRCA2-RAD51 axis is essential for homologous recombination repair (HRR) and is frequently disrupted in breast cancers. PARP inhibitors (PARPis) are used clinically to treat BRCA-mutated breast tumors. Using a genetic screen, we identified EMI1 as a modulator of PARPi sensitivity in triple-negative breast cancer (TNBC) cells. This function requires the F-box domain of EMI1, through which EMI1 assembles a canonical SCF ubiquitin ligase complex that constitutively targets RAD51 for degradation. In response to genotoxic stress, CHK1-mediated phosphorylation of RAD51 counteracts EMI1-dependent degradation by enhancing RAD51's affinity for BRCA2, leading to RAD51 accumulation. Inhibition of RAD51 degradation restores HRR in BRCA1-depleted cells. Human breast cancer samples display an inverse correlation between EMI1 and RAD51 protein levels. A subset of BRCA1-deficient TNBC cells develop resistance to PARPi by downregulating EMI1 and restoring RAD51-dependent HRR. Notably, reconstitution of EMI1 expression reestablishes PARPi sensitivity both in cellular systems and in an orthotopic mouse model.
This paper references
High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation
A. Parplys (2015)
Assay for human Rad51-mediated DNA displacement loop formation.
Steven Raynard (2009)
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.
A. Pierce (1999)
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
C. Sørensen (2005)
Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis.
E. Raderschall (2002)
Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells.
P. M. Kim (2001)
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APCCdh1
J. Y. Hsu (2002)
Identification of a family of human F-box proteins
C. Cenciarelli (1999)
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition
A. Wiegmans (2015)
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
P. M. Schoonen (2017)
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Richard W Martin (2007)
Biochemical studies on human Rad51-mediated homologous recombination.
Y. Kwon (2011)
Degradation of Cep68 and PCNT cleavage mediate Cep215 removal from the PCM to allow centriole separation, disengagement and licensing
Julia K. Pagan (2015)
I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks.
Amanda Gunn (2012)
Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability
D. Schild (2010)
In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis
Srividya Vaidyanathan (2016)
Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors.
N. Lehman (2007)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A. Yazinski (2017)
Links between genome integrity and BRCA1 tumor suppression.
M. Li (2012)
Mechanisms and function of substrate recruitment by F-box proteins
J. Skaar (2013)
Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair
Nicole Bennardo (2008)
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch (2011)
The consequences of Rad51 overexpression for normal and tumor cells.
H. Klein (2008)
Expression of BRC Repeats in Breast Cancer Cells Disrupts the BRCA2-Rad51 Complex and Leads to Radiation Hypersensitivity and Loss of G2/M Checkpoint Control*
C. F. Chen (1999)
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27
R. Cesari (2003)
EMI1, a three-in-one ubiquitylation inhibitor
H. Yamano (2013)
Identification and characterization of essential genes in the human genome
T. Wang (2015)
Gene essentiality and synthetic lethality in haploid human cells
V. Blomen (2015)
Basis for Avid Homologous DNA Strand Exchange by Human Rad51 and RPA*
S. Sigurdsson (2001)
Structural analysis of the human Rad51 protein-DNA complex filament by tryptophan fluorescence scanning analysis: transmission of allosteric effects between ATP binding and DNA binding.
Axelle Renodon-Cornière (2008)
Control of Meiotic and Mitotic Progression by the F Box Protein β-Trcp1 In Vivo
D. Guardavaccaro (2003)
Bipartite stimulatory action of the Hop2-Mnd1 complex on the Rad51 recombinase.
P. Chi (2007)
Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer
H. Maacke (2000)
Selective Enhancing Effect of Early Mitotic Inhibitor 1 (Emi1) Depletion on the Sensitivity of Doxorubicin or X-ray Treatment in Human Cancer Cells*
Natsumi Shimizu (2013)
FBH1 promotes DNA double-strand breakage and apoptosis in response to DNA replication stress
Yeon-Tae Jeong (2013)
Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability
C. Richardson (2004)
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
Jiewen Zhu (2013)
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Y. Liu (2016)
Mouse emi1Has an Essential Function in Mitotic Progression during Early Embryogenesis
H. Lee (2006)
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
This paper is referenced by
Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination
Tahereh Mohammadian Gol (2019)
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
S. Cocco (2020)
University of Groningen Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells Schoonen,
Pepijn M. Schoonen (2019)
F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy.
Aleksandra I Adamovich (2019)
Efficient Representations of Tumor Diversity with Paired DNA-RNA Aberrations
Qian Ke (2020)
Knockout Mouse Models Provide Insight into the Biological Functions of CRL1 Components.
Tadashi Nakagawa (2020)
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation
R. D. Jachimowicz (2019)
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2‐deficient cancer cells
P. M. Schoonen (2019)
Ubiquitin signaling in cell cycle control and tumorigenesis.
Fabin Dang (2020)
Triple-negative breast cancer therapy: Current and future perspectives (Review)
Kwang-Ai Won (2020)
PHOTACs enable optical control of protein degradation
Martin Reynders (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
H. Li (2020)
PARP and PARG inhibitors in cancer treatment.
Dea Slade (2020)
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer
Andrä Brunner (2020)
FBXW10 promotes hepatocarcinogenesis in male patients and mice.
Yuan-Deng Luo (2019)
Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment
Shahd Fouad (2019)
Discriminative SKP2 interactions with CDK-cyclin complexes support a cyclin A-specific role in p27KIP1 degradation
Marco Salamina (2020)
Emerging roles of F-box proteins in cancer drug resistance.
Linzhi Yan (2019)
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
E. Lee (2020)
Targeting dePARylation for cancer therapy
M. A. Kassab (2020)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Keung (2019)
Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer Cells
Dina Moustafa (2020)